Insmed Incorporated has announced the appointment of Clementia Pharmaceuticals President and CEO Clarissa Desjardins to its board of directors and the promotions of Roger Adsett to Chief Operating Officer and Drayton Wise to Senior VP, Head of United States. The company also recently announced the appointment of Martina Flammer as Chief Medical Officer and provided an update on its Arikayce amikacin liposome inhalation suspension.
Desjardins founded Clementia in 2011 and has served as its CEO since then. She was previously CEO and a board member of the Centre of Excellence in Personalized Medicine (CEPMED). In addition to Clementia, she had founded or co-founded two other companies, Caprion Pharmaceuticals and Advanced Bioconcept.
Insmed Chairman and CEO Will Lewis commented, “Insmed is accelerating its efforts to bring Arikayce to patients around the world. In order to accomplish this and continue to develop our pipeline, we are making the appropriate leadership and related changes to enhance our global operations. At the board level, this means adding individuals with exceptional talent and skill sets to help advise and direct management on this journey. We are thrilled with the addition of Clarissa to our board of directors. Clarissa brings over two decades of scientific and industry experience across multiple functional roles, including therapeutic product development, finance, business development and intellectual property management to our board.”
Desjardins said, “I’m excited to join the board at this important point in Insmed’s evolution into a global commercial organization. I believe my industry experience and expertise in rare diseases will serve the company well as we work to advance Insmed’s mission to transform the lives of patients with serious and rare diseases. I look forward to working with the Insmed management team and other board members going forward.”
Lewis also said, “In addition to enhancing our board of directors, I am also excited to expand the responsibilities of Roger Adsett through his appointment to the newly created role of Chief Operating Officer. Roger has shown tremendous leadership during our first year of commercial launch in the US while also leading the effort to establish the key elements of our global infrastructure. In his new role, he will now be able to direct on a comprehensive basis the advancement of Arikayce and our pipeline products through development, and potential approval and commercial launch in all regions.”
“I am also pleased to announce the promotion of Drayton Wise to SVP, Head of United States which will enable him to further oversee the continued success of Arikayce. As General Manager worldwide for this product, Drayton has played a pivotal role in the successful commercial launch of Arikayce, and in his new role he will have the ability to replicate the elements of that successful launch and apply them to our pipeline products,” Lewis added.
Read the Insmed press release.
